GetTopicDetailResponse(id=536016532df, topicName=Solanezumab, introduction=Solanezumab, content=null, image=null, comments=3, allHits=1399, url=https://h5.medsci.cn/topic?id=16532, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=16796, tagList=[TagDto(tagId=16796, tagName=Solanezumab)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2118654, encodeId=c51a2118654b5, content=52名攜帶突變的參與者被分配接受<a href='/topic/show?id=013fe83352' target=_blank style='color:#2F92EE;'>#gantenerumab#</a>治療，52名參與者接受<a href='/topic/show?id=536016532df' target=_blank style='color:#2F92EE;'>#Solanezumab#</a>治療，另外40名參與者接受安慰劑治療。兩種藥物都涉及其Aβ靶點(diǎn)，但與對(duì)照組相比，都沒(méi)有顯示出對(duì)認(rèn)知能力的有益影響。<a href='/topic/show?id=e3009e77006' target=_blank style='color:#2F92EE;'>#阿爾茲海默癥#</a>，太難了，又倒下兩個(gè), objectTitle=Nat Med：遺憾，Gantenerumab或Solanezumab對(duì)于顯性遺傳阿爾茲海默癥無(wú)效, objectType=article, longId=213067, objectId=919921306ed9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/142214-forgetting.jpg, objectUrl=/article/show_article.do?id=919921306ed9, replyNumber=0, likeNumber=167, createdTime=2023-03-10, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=919921306ed9, moduleTitle=Nat Med：遺憾，Gantenerumab或Solanezumab對(duì)于顯性遺傳阿爾茲海默癥無(wú)效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=919921306ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039462, encodeId=911920394625b, content=<a href='/topic/show?id=536016532df' target=_blank style='color:#2F92EE;'>#Solanezumab#</a>, objectTitle=Nat Med：遺憾，Gantenerumab或Solanezumab對(duì)于顯性遺傳阿爾茲海默癥無(wú)效, objectType=article, longId=213067, objectId=919921306ed9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=919921306ed9, replyNumber=0, likeNumber=102, createdTime=2022-06-06, rootId=0, userName=12498ef1m31(暫無(wú)昵稱(chēng)), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=919921306ed9, moduleTitle=Nat Med：遺憾，Gantenerumab或Solanezumab對(duì)于顯性遺傳阿爾茲海默癥無(wú)效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=919921306ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039461, encodeId=6c1720394618d, content=<a href='/topic/show?id=536016532df' target=_blank style='color:#2F92EE;'>#Solanezumab#</a>, objectTitle=NEJM：阿爾茨海默病新藥Solanezumab III期臨床試驗(yàn)失敗, objectType=article, longId=30355, objectId=46a930355d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46a930355d0, replyNumber=0, likeNumber=90, createdTime=2015-01-18, rootId=0, userName=12498ef1m31(暫無(wú)昵稱(chēng)), userId=d2f42500210, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46a930355d0, moduleTitle=NEJM：阿爾茨海默病新藥Solanezumab III期臨床試驗(yàn)失敗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=46a930355d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話(huà)題小助手
2020-05-29
